Corvus Pharmaceuticals Inc (CRVS) Q3 2024 Earnings Call Highlights: Strategic Advancements Amid ...

By Yahoo! Finance | Nov 13, 2024 at 02:24 AM EST

CEO Richard Miller discusses the quick response kinetics of ITK inhibition on atopic dermatitis in the earnings call. Initial improvements are expected within a week, with a durable effect similar to other approved agents. Data will be reported in December, with responses evaluated over a two-month period.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.